The BNF for Children is the unrivalled guidance on prescribing, dispensing and administering medicines to children.
BNF for Children is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors in paediatrics.
SubscribeContent Updates
Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients
Evidence Grading: As part of NICE accreditation recommendations, BNFc content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making
Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you access only the very latest prescribing knowledge
Worldwide credibility: The BNFc uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely
*based on average data in the last 12 months
This update contains 7 significant changes, and 1 new monograph.
Significant Changes:
• COVID-19 vaccine: updated guidance in-line with Public Health England recommendations.
• Diabetic hyperglycaemic emergencies: updated guidance.
• Diabetic Ketoacidosis: title changed to Diabetic hyperglycaemic emergencies.
• Immunisation schedule: updated National flu immunisation programme in-line with Public Health England recommendations.
• Influenza vaccine: updated guidance in-line with Public Health England recommendations.
• Remdesivir: update to treatment duration.
• Trientine dihydrochloride: name change to trientine, and update to dosing for Wilson’s disease.
New Monographs:
• Adakveo® [crizanlizumab].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 4 significant changes and 3 new monographs.
Significant Changes:
• Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years [MHRA/CHM advice].
• Migraine: updated guidance on preventative migraine treatment.
• Neonatal infection, antibacterial therapy: new guidance on management.
• Oral retinoid medicines: temporary monitoring advice during coronavirus (COVID-19) pandemic [MHRA/CHM advice] (advice in acitretin, isotretinoin; see example in isotretinoin).
New Monographs:
• Evrysdi® [risdiplam].
• Fintepla® [fenfluramine].
• Taltz® [ixekizumab].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 5 significant changes, 1 dose change, 2 new monographs, 2 new preparations and 1 deleted monograph.
Significant Changes:
• Atezolizumab (Tecentriq®) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) [MHRA/CHM advice] (advice in ipilimumab, pembrolizumab; see example in ipilimumab).
• COVID-19 vaccine: reports of myocarditis and pericarditis with the Pfizer/BioNTech and Moderna vaccines.
• Immunoglobulins: updated guidance in-line with Public Health England recommendations for the use of immunoglobulin for tetanus infection and prophylaxis.
• Prescribing in renal impairment: updated guidance.
• Tetanus vaccine: updated guidance in-line with Public Health England recommendations.
Dose Change:
• Valganciclovir [removal of dose equivalence statement].
New Monographs:
• Dificlir® [fidaxomicin].
• Keytruda® [pembrolizumab].
New Preparations: Fixkoh Airmaster® [fluticasone with salmeterol]; Kigabeq® [vigabatrin].
Deleted Monograph: Tetrahydrobiopterin.
For further details on changes in the BNF for Children click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 10 significant changes, 1 dose change, 2 new monographs and 1 deleted monograph.
Significant Changes:
• Contraceptives, interactions: updated guidance.
• COVID-19: updated guidance.
• COVID-19 vaccine: updated guidance in-line with Public Health England recommendations.
• Eczema: updated guidance on the management of infection.
• Emergency contraception: updated guidance.
• Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products [MHRA/CHM advice].
• Oral anticoagulants: updated guidance in overview.
• Rabies vaccine: addition of new guidance for post-exposure management.
• Skin infections, antibacterial therapy: new guidance for the management of secondary bacterial infection of common skin conditions.
• Vitamins: addition of new guidance for vitamin D.
Dose Change:
• Perampanel [update to include dosing in children from 4 years old for treatment of focal seizures and from 7 years old for primary generalised tonic-clonic seizures].
New Monographs:
• Ruconest® [conestat alfa].
• Ultomiris® [ravulizumab].
Deleted Monograph: Emollient bath and shower products, tar-containing.
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 8 significant changes, 6 dose changes and 2 new preparations.
Significant Changes:
• Esomeprazole: updated breast feeding statement.
• Hypoglycaemia: updated guidance.
• Immune thrombocytopenic purpura: updated guidance.
• Lansoprazole: updated breast feeding statement.
• Life support algorithm (image): newborn life support algorithm, paediatric advanced life support algorithm, and paediatric basic life support algorithm images updated.
• Life support algorithm (image): paediatric out-of-hospital basic life support algorithm image added.
• Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration [MHRA/CHM advice] (advice in macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride, macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride; see example in macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride).
• Sodium nitrite: risk of death from unintended administration of sodium nitrite [NPSA advice].
Dose Changes:
• Amiodarone hydrochloride [update to dosing for the treatment of ventricular fibrillation or pulseless ventricular tachycardia refractory to defibrillation (for cardiopulmonary resuscitation)].
• Budenofalk® capsules and granules (budesonide) [update to dosing for microscopic colitis].
• Entocort® capsules (budesonide) [update to dosing for microscopic colitis].
• Glucose [update to dosing for hypoglycaemia].
• Medical emergencies in the community [update to dosing of glucose for hypoglycaemia].
• Naloxone hydrochloride [update to dosing for treatment of acute opioid overdosage including high- and low-dose regimens].
New Preparations:
• Miprosed® [midazolam].
• Ozalin® [midazolam].
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 4 significant changes, 2 dose changes and 1 new monograph.
Significant Changes:
• Anthrax: updated guidance.
• Botulism antitoxin: updated guidance.
• Pneumococcal vaccine: new guidance added on prioritisation of the 23-valent pneumococcal vaccine while supplies remain limited.
• Poisoning, emergency treatment: new guidance on storage of specialist antidotes.
Dose Changes:
• Dupilumab [update to include dosing in children from 6 years old for severe atopic eczema].
• Oxycodone hydrochloride [update to include oral dosing in children from 12 years old for severe pain].
New Monograph:
• Latuda® [lurasidone hydrochloride].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
